Cingulate (CING, Financial) revealed encouraging top-line outcomes from the CTx-1301-013 trial, which was required by the FDA. The study focused on examining how food impacts the absorption of the highest dose of their leading candidate, CTx-1301. This innovative investigational tablet, in an extended-release form, contains dexmethylphenidate, a drug already approved by the FDA for treating Attention Deficit/Hyperactivity Disorder. The findings indicated that the 50mg dose of CTx-1301 can be effectively administered with or without food. Various pharmacokinetic measurements were taken, affirming that the side effects align with past data, suggesting a favorable tolerability profile.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Cingulate Inc (CING, Financial) is $32.40 with a high estimate of $62.00 and a low estimate of $8.00. The average target implies an upside of 644.83% from the current price of $4.35. More detailed estimate data can be found on the Cingulate Inc (CING) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Cingulate Inc's (CING, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
